-
公开(公告)号：US20200289631A1
公开(公告)日：2020-09-17
申请号：US16887765
申请日：2020-05-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/725 , C07K14/74 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574 , C07K16/28 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
302.发明申请公开(公告)号：US20200268861A1
公开(公告)日：2020-08-27
申请号：US16851627
申请日：2020-04-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Jens FRITSCHE , Harpreet SINGH , Andrea MAHR , Martina OTT , Claudia WAGNER , Oliver SCHOOR
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C07K16/18 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
303.发明申请公开(公告)号：US20200268799A1
公开(公告)日：2020-08-27
申请号：US16871156
申请日：2020-05-11
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
304.发明申请公开(公告)号：US20200261505A1
公开(公告)日：2020-08-20
申请号：US16833146
申请日：2020-03-27
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , C07K16/28 , A61K39/395 , C07K16/24 , A61K39/12 , A61K39/00 , C12N5/0783 , A61K45/06 , A61P35/02 , C07K14/47 , A61K38/08 , C07K14/54 , C07K7/06 , A61K39/39 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
305.发明申请公开(公告)号：US20200261504A1
公开(公告)日：2020-08-20
申请号：US16833110
申请日：2020-03-27
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , C07K16/28 , A61K39/395 , C07K16/24 , A61K39/12 , A61K39/00 , C12N5/0783 , A61K45/06 , A61P35/02 , C07K14/47 , A61K38/08 , C07K14/54 , C07K7/06 , A61K39/39 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
306.发明申请公开(公告)号：US20200147192A1
公开(公告)日：2020-05-14
申请号：US16748350
申请日：2020-01-21
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Jens FRITSCHE , Harpreet SINGH , Andrea MAHR , Martina OTT , Claudia WAGNER , Oliver SCHOOR
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C07K16/18 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
307.发明申请公开(公告)号：US20200108097A1
公开(公告)日：2020-04-09
申请号：US16703061
申请日：2019-12-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , C07K16/24 , A61K39/00 , C07K14/47 , C07K16/28 , A61K39/12 , C07K14/54 , C07K7/06 , A61P35/02 , A61P35/00 , A61K45/06 , C12N5/0783 , A61K39/395 , A61K39/39 , A61K38/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
308.发明申请公开(公告)号：US20200093862A1
公开(公告)日：2020-03-26
申请号：US16703034
申请日：2019-12-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61K39/00 , C07K16/28 , C07K14/47 , C07K14/54 , C07K7/06 , A61P35/02 , A61K39/12 , A61K38/08 , C07K16/24 , A61K39/39 , A61K39/395 , C12N5/0783 , A61K45/06 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
309.发明申请公开(公告)号：US20200085874A1
公开(公告)日：2020-03-19
申请号：US16692108
申请日：2019-11-22
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , C07K16/24 , A61K39/12 , C07K14/47 , A61K39/00 , C07K14/54 , C07K7/06 , A61P35/02 , A61K38/08 , C07K16/28 , A61K39/395 , A61K45/06 , A61K39/39 , C12N5/0783 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20200078439A1
公开(公告)日：2020-03-12
申请号：US16510442
申请日：2019-07-12
Applicant: Immatics Biotechnologies GmbH
Inventor： Hans Georg RAMMENSEE , Stefan STEVANOVIC , Cecile GOUTTEFANGEAS , Toni WEINSCHENK , Peter LEWANDROWSKI
Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
Search Results
623
records
(took 0.028 seconds)
